Online inquiry

IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ14988MR)

This product GTTS-WQ14988MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 1
Species	Chimeric
RefSeq	NM_001178098.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	930
UniProt ID	P15391

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14988MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ4197MR	IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	BIIB019
GTTS-WQ14094MR	IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	REGN-421
GTTS-WQ528MR	IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 0, Pseudo-UTP, 30 nt-poly(A))	mRNA	4D11
GTTS-WQ2259MR	IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	ALX-0171
GTTS-WQ5593MR	IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	CDP7766
GTTS-WQ11160MR	IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	MDX-1333
GTTS-WQ1079MR	IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	ABBV-838
GTTS-WQ4704MR	IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 1, 2-Thio-UTP, 120 nt-poly(A))	mRNA	BMS-986168

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST